207 related articles for article (PubMed ID: 27062421)
21. CALCITONIN SECRETORY INDEX AND UNSUSPECTED NODAL DISEASE IN MEDULLARY THYROID CARCINOMA.
Filimon S; Payne RJ; Black MJ; Hier MP; Mlynarek AM; Forest VI; Tamilia M
Endocr Pract; 2018 May; 24(5):460-467. PubMed ID: 29847167
[TBL] [Abstract][Full Text] [Related]
22. Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature.
Trimboli P; Giovanella L
Clin Chem Lab Med; 2015 Sep; 53(10):1507-14. PubMed ID: 25781697
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic value of selected biochemical markers in the detection of recurrence of medullary thyroid cancer - comparison of calcitonin, procalcitonin, chromogranin A, and carcinoembryonic antigen.
Woliński K; Kaznowski J; Klimowicz A; Maciejewski A; Łapińska-Cwojdzińska D; Gurgul E; Car AD; Fichna M; Gut P; Gryczyńska M; Ruchała M
Endokrynol Pol; 2017; 68(4):434-437. PubMed ID: 28585679
[TBL] [Abstract][Full Text] [Related]
24. Calcium-stimulated calcitonin - The "new standard" in the diagnosis of thyroid C-cell disease - clinically relevant gender-specific cut-off levels for an "old test".
Niederle MB; Scheuba C; Gessl A; Li S; Koperek O; Bieglmayer C; Riss P; Selberherr A; Niederle B
Biochem Med (Zagreb); 2018 Oct; 28(3):030710. PubMed ID: 30429678
[TBL] [Abstract][Full Text] [Related]
25. Biomarkers of medullary thyroid cancer in the prediction of cure after thyroidectomy.
Nien FJ; Chang TC
J Formos Med Assoc; 2015 Sep; 114(9):793-4. PubMed ID: 23906686
[No Abstract] [Full Text] [Related]
26. Preoperative calcitonin testing improves the diagnosis of medullary thyroid carcinoma in female and male patients.
Weber T; Poplawski A; Vorländer C; Dotzenrath C; Ringelband R; Schabram J; Passler C; Zielke A; Schlegel N; Nies C; Krenz D; Jähne J; Schwab R; Bartsch DK; Binnebösel M; Kemen M; Klinger C; Buhr H; Lorenz K
Eur J Endocrinol; 2022 Jan; 186(2):223-231. PubMed ID: 34871180
[TBL] [Abstract][Full Text] [Related]
27. Calcitonin negative Medullary Thyroid Carcinoma: a challenging diagnosis or a medical dilemma?
Gambardella C; Offi C; Patrone R; Clarizia G; Mauriello C; Tartaglia E; Di Capua F; Di Martino S; Romano RM; Fiore L; Conzo A; Conzo G; Docimo G
BMC Endocr Disord; 2019 May; 19(Suppl 1):45. PubMed ID: 31142313
[TBL] [Abstract][Full Text] [Related]
28. Calcitonin-negative medullary thyroid carcinoma: the 'triple-negative' phenotype.
Murphy DC; Johnson SJ; Aspinall S
Ann R Coll Surg Engl; 2020 Mar; 102(3):e63-e66. PubMed ID: 31841033
[TBL] [Abstract][Full Text] [Related]
29. Medullary thyroid carcinoma without marked elevation of calcitonin: a diagnostic and surveillance dilemma.
Wang TS; Ocal IT; Sosa JA; Cox H; Roman S
Thyroid; 2008 Aug; 18(8):889-94. PubMed ID: 18651827
[TBL] [Abstract][Full Text] [Related]
30. Time Kinetics and prognosis roles of calcitonin after surgery for medullary thyroid carcinoma.
Guo F; Fu G; Li F; Hua Y; Wang Z; Zheng X; Zhao J; Gao M
World J Surg Oncol; 2024 May; 22(1):121. PubMed ID: 38711029
[TBL] [Abstract][Full Text] [Related]
31. Can procalcitonin be useful for medullary thyroid cancer?
Kaczka K; Mikosiński S; Fendler W; Jałocha-Kaczka A; Pomorski L
Endokrynol Pol; 2010; 61(5):430-6. PubMed ID: 21049453
[TBL] [Abstract][Full Text] [Related]
32. A cut-off value of basal serum calcitonin for detecting macroscopic medullary thyroid carcinoma.
Kwon H; Kim WG; Choi YM; Jang EK; Jeon MJ; Song DE; Baek JH; Ryu JS; Hong SJ; Kim TY; Kim WB; Shong YK
Clin Endocrinol (Oxf); 2015 Apr; 82(4):598-603. PubMed ID: 25041034
[TBL] [Abstract][Full Text] [Related]
33. Procalcitonin as a postoperative marker in the follow-up of patients affected by medullary thyroid carcinoma.
Trimboli P; Lauretta R; Barnabei A; Valabrega S; Romanelli F; Giovanella L; Appetecchia M
Int J Biol Markers; 2018 May; 33(2):156-160. PubMed ID: 29707993
[TBL] [Abstract][Full Text] [Related]
34. Carcinoembryonic antigen levels correlated with advanced disease in medullary thyroid cancer.
Turkdogan S; Forest VI; Hier MP; Tamilia M; Florea A; Payne RJ
J Otolaryngol Head Neck Surg; 2018 Sep; 47(1):55. PubMed ID: 30223887
[TBL] [Abstract][Full Text] [Related]
35. Mild to moderate increase of serum calcitonin levels only in presence of large medullary thyroid cancer deposits.
Pelizzo MR; Torresan F; Da Roit A; Merante Boschin I; Chondrogiannis S; Rampin L; Colletti PM; Vinjamury S; Perkins AJ; Rubello D
Rev Esp Med Nucl Imagen Mol; 2015; 34(6):378-82. PubMed ID: 26420439
[TBL] [Abstract][Full Text] [Related]
36. Cure and survival of sporadic medullary thyroid carcinoma following systematic preoperative calcitonin screening.
Torresan F; Mian C; Cavedon E; Iacobone M
Langenbecks Arch Surg; 2019 Jun; 404(4):411-419. PubMed ID: 30903267
[TBL] [Abstract][Full Text] [Related]
37. Progression of postoperative residual medullary thyroid carcinoma as monitored by plasma calcitonin levels.
Tisell LE; Dilley WG; Wells SA
Surgery; 1996 Jan; 119(1):34-9. PubMed ID: 8560383
[TBL] [Abstract][Full Text] [Related]
38. [Evaluation of efficacy and clinical impact of 18F-FDG-PET in the diagnosis of recurrent medullary thyroid cancer with increased calcitonin and negative imaging test].
Gómez-Camarero P; Ortiz-de Tena A; Borrego-Dorado I; Vázquez-Albertino RJ; Navarro-González E; Ruiz-Franco-Baux JV; Cuenca-Cuenca JI
Rev Esp Med Nucl Imagen Mol; 2012 Sep; 31(5):261-6. PubMed ID: 23067528
[TBL] [Abstract][Full Text] [Related]
39. [Routine serum calcitonin measurement in thyroid nodules].
Storani ME; Bostico ST; Subies FA; Musich M; Oneto A
Medicina (B Aires); 2019; 79(4):271-275. PubMed ID: 31487246
[TBL] [Abstract][Full Text] [Related]
40. Integration of a postoperative calcitonin measurement into an anatomical staging system improves initial risk stratification in medullary thyroid cancer.
Yang JH; Lindsey SC; Camacho CP; Valente FO; Germano-Neto F; Machado AL; Mamone MC; Brodskyn F; Biscolla RP; Tuttle RM; Dias-da-Silva MR; Maciel RM
Clin Endocrinol (Oxf); 2015 Dec; 83(6):938-42. PubMed ID: 25376110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
